SCHEMBL16987259

SCHEMBL16987259

COP(O[C@H]1C[C@H](n2ccc(N)nc2=O)O[C@@H]1CO)N(C(C)C)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
PDE3A Q14432 3/20 0.45
CACNA1F O60840 2/20 0.45
ALB P02768 2/20 0.45
MAPT P10636 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
THRB P10828 1/20 0.44
MTOR P42345 1/20 0.44
MDM2 Q00987 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
POLB P06746 2/20 0.43
PDE4D Q08499 1/20 0.42
SLC29A1 Q99808 1/20 0.42
POLG P54098 2/20 0.40
ADRB1 P08588 1/20 0.39
DNMT1 P26358 1/20 0.39
P2RY2 P41231 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8517853 0.87 LMNA (0.40) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL16359951 0.83 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL10431788 0.83 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL10432426 0.83 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL3186275 0.82 LMNA (0.52) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL26828669 0.82 LMNA (0.49) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL4579459 0.80 LMNA (0.56) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL4579454 0.80 LMNA (0.56) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL16987260 0.80 PDE3A (0.45) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL25082259 0.79 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414790-B2 Exocyclic nitrogen atom protected nucleoside and method for producing and using the same THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2019-09-17 US disclosed
US-20150225442-A1 EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414790-B2 Exocyclic nitrogen atom protected nucleoside and method for producing and using the same NT5C3B, RNGTT, UMPS LMNA 897/4885PDE3A 2898/4885CACNA1F 4827/4885
US-20150225442-A1 EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME NSUN2, RNGTT, NT5C3B LMNA 632/4885PDE3A 3200/4885CACNA1F 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.